The Conversation (0)
CareDx (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced today that Olerup QTYPE, the fastest real time Human Leukocyte Antigen (HLA) typing diagnostic, has received CE Mark approval and is available on both Roche and Applied Biosystems platforms. As quoted in …
CareDx (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced today that Olerup QTYPE, the fastest real time Human Leukocyte Antigen (HLA) typing diagnostic, has received CE Mark approval and is available on both Roche and Applied Biosystems platforms.
As quoted in the press release:
Olerup QTYPE provides tissue typing laboratories with the most suitable product for real time HLA typing of donors and recipients of organ transplants. The workflow is simple and the test is performed within the hour, faster than any other available product on the market. Olerup QTYPE is currently available on both Roche LightCycler® and Applied Biosystems® platforms. The mass majority of the real time typing market is covered by these two platforms, giving QTYPE wide market availability.
“We are excited to announce this milestone of broad commercialization of Olerup QTYPE. Between the CE Mark and launch on both PCR platforms, HLA laboratories across the world will have access to the fastest typing solution. With 50% of transplant labs worldwide using Olerup products today, we will continue to utilize our current relationships to provide this innovative solution,” said Peter Maag, CEO at CareDx.